Proposed Guidelines for the Diagnosis of Canine Idiopathic Dilated Cardiomyopathy

The ESVC Taskforce for Canine Dilated Cardiomyopathy

Joanna Dukes-McEwan1; Michele Borgarelli2; Anna Tidholm3; Andrea C Vollmar4; Jens Hägström5

Abstract

Dilated cardiomyopathy (DCM) is a major cause of morbidity and mortality in various dog breeds. The diagnosis of overt DCM is not normally problematic, although the importance of active exclusion of other causes of the dilated, hypokinetic heart is emphasised. Recent interest in human familial DCM has prompted a number of researchers to investigate the genetic basis of canine DCM. Prospective screening of dogs from lines with familial prevalence of DCM may identify dogs with pre-clinical ("occult") DCM. Dogs with other echocardiographic abnormalities or arrhythmias may also be identified. It is clear that dogs, like humans, have a prolonged pre-symptomatic phase of the disease extending over years. The ESVC DCM taskforce was established to provide the veterinary cardiology community with guidelines for the diagnosis of DCM, predominantly based on 2D and M-mode echocardiography. Diagnosis of DCM requires all of the following: (i) Left ventricular dilatation (ii) Reduced systolic function (iii) Increased sphericity of the left ventricle. We propose a scoring system for the identification of dogs in the pre-clinical stages. These include a number of major criteria and minor criteria. Future prospective longitudinal studies are required to test these in different breed populations to assess their predictive power and further refinements may be required. The importance of post mortem confirmation of disease is emphasised, and the two major histopathological features associated with DCM, the attenuated wavy fibre and the fibro-fatty infiltration-degenerative forms, require further investigation to identify the different aetiopathogenetic factors which may be involved.

Key words: Dog, Dilated Cardiomyopathy, Echocardiography, Histopathology, Familial Dilated Cardiomyopathy

Introduction

Cardiomyopathies are defined as diseases of the myocardium associated with cardiac dysfunction. The new classification of cardiomyopathies by the World Health Organisation is by dominant pathophysiology or, where possible, by aetiological / pathogenic factors. Dilated cardiomyopathy is defined as being characterised by dilatation and impaired contraction of the left ventricle or both ventricles. The diagnosis of idiopathic dilated cardiomyopathy (DCM) requires the active exclusion of other cardiac, pulmonary or systemic disease which may secondarily induce a similar phenotype.

Dilated cardiomyopathy is prevalent in certain breeds of dog and is rare in cross breeds. Furthermore, DCM is strongly familial in some breeds, and canine DCM has long been suspected to have a genetic basis. In contrast, it has only been in the last decade that human DCM has been recognised to have a genetic basis in an important subset of about 30% of cases. Various modes of inheritance have been reported, but autosomal dominant transmission is

1 BVMS, MVM, PhD, DVC, MRCVS, Dip-ECVIM-CA (Cardiology), Cardiology Service, Institute of Comparative Medicine, Division of Small Animal Clinical Studies, Dept. Veterinary Clinical Studies, University of Glasgow Veterinary School, Bearsden, Glasgow G61 1QH, Scotland, UK. E-mail: J.Dukes-McEwan@vet.gla.ac.uk
2 DVM, Dip-ECVIM-CA (Cardiology); Dott. veterinary clinic, Via Leonardo Da Vinci 44, 10095 Grugliasco, Italy.
3 DVM, Dip-ECVIM-CA (Cardiology); Small Animal Vet Clinic, Wissen, Germany.
4 DVM, PhD, Dip-ECVIM-CA (Cardiology); Dept. of Small Animal Medicine and Surgery, Faculty of Veterinary Medicine, Uppsala, Sweden.
5 DVM, PhD, Dip-ECVIM-CA (Cardiology); Dept. Veterinary Clinical Studies, University of Glasgow Veterinary School, Bearsden, Glasgow G61 1QH, Scotland, UK.
most commonly reported for non-syndromic DCM in humans (i.e. not associated with skeletal myopathy or other phenotype), with over thirteen different loci described\(^{1}\). In a specific dog breed, which represents a closed population, DCM is fairly uniform and it is probable that a similar genetic aetiology underlies the cause of DCM within a breed. Phenocopies (e.g. ischaemic cardiomyopathy, excessive alcohol consumption, myocarditis) are less common than in human patients. In dogs, an autosomal dominant transmission has been reported in Irish Wolfhounds\(^{2}\), Newfoundlands\(^{3}\) and Dobermanns\(^{4}\). Other modes of transmission have been reported in other breeds\(^{8,9}\).

**Epidemiology**

Dilated cardiomyopathy has been reported to have an overall prevalence of 0.5%, based on the Veterinary Medical Database at Purdue University for the period 1986 - 1991\(^{10}\). This only included dogs with clinical signs referable to heart disease, particularly congestive heart failure. Further analysis showed higher prevalence in pedigree dogs (0.65%) compared with cross-breeds (0.16%), and prevalence in certain specific breeds was very high (e.g. Deerhounds 6.0%; Dobermanns, 5.8%; Irish Wolfhounds, 5.6%; great Danes, 3.9%; Boxers, 3.4%; Newfoundlands, 1.3%). Large and giant breed dogs are most predisposed to develop DCM, with the exception of spaniel breeds (especially Cocker Spaniels (English and American)). Prevalence increases with age, and males are usually reported as being over-represented\(^{11}\) in the population of dogs with congestive heart failure. Prevalence rates are much higher in prospective studies screening for the presence of DCM, when dogs without clinical signs may be detected (e.g. Dobermanns, 63.2%\(^{11}\); Irish Wolfhounds, 24.2%\(^{12}\); Newfoundlands, 17.6%)\(^{13}\). It should, however, be noted that concentration on certain family lines in these studies may over-estimate actual population prevalence. In these prospective studies, there is not usually a marked sex-predisposition reported, although male dogs may show an earlier onset of congestive heart failure\(^{4}\).

**Natural history of the disease**

Increasing interest in screening families of dogs where DCM is prevalent has led to an appreciation that there is a very long phase of the disease which is not associated with clinical signs evident to the owner or veterinary surgeon. Indeed, the phase with clinical signs, usually associated with the presence of congestive heart failure, is the final stage of several years of insidious progression. Identification of this pre-clinical phase may be challenging to diagnose and one of the aims of this paper is to provide cardiologists with criteria on which to base a diagnosis.

Dogs which are initially normal gradually progress through these pre-clinical stages to eventually develop congestive failure, or sudden death may intervene at any stage. In dogs with an older age of onset, it is possible that concurrent illness is responsible for their death prior to any recognition of DCM.

**Survival**

Prediction of survival times and identification of factors influencing mortality in the canine patient with DCM is of interest for dog owners as well as veterinarians. Predictive factors of survival rate in different studies include clinical class of heart failure, presence of pleural effusion and pulmonary oedema, echocardiographic parameters, the presence of ventricular premature complexes (VPCs), and presence of biventricular heart failure and atrial fibrillation (in Doberman Pinschers\(^{14}\)). In one study of 189 dogs with DCM only three of 27 tested variables were shown to influence survival, i.e. young age at presentation, dyspnoea and ascites\(^{15}\). Another study of 37 dogs of various breeds identified pleural effusion and pulmonary oedema as independent prognostic indicators for dogs with DCM\(^{16}\). These studies did not find breed (e.g. Dobermanns) or parameters of systolic function to be significant prognostic indicators in canine DCM.

Survival times in different studies are compared in Table 1. Survival rate at one year was exceptionally low in a study of Dobermanns\(^{17}\), which may indicate that the fatty infiltration - degenerative type of DCM carries a worse prognosis compared with the attenuated wavy fibre type of DCM (see histopathology section). Medical treatment, especially ACE inhibitors and beta-blockers, may influence survival in dogs with congestive heart failure, but this was only evaluated in two of the studies. However, as the administration of ACE inhibitors and beta-blockers varied considerably, this may also be a source of variation of survival times between the studies (Table 1).

**Histopathological characteristics of DCM**

Gross pathology examination of dogs with DCM generally shows dilatation of either all four cardiac chambers or predominant dilatation of the left chambers. Myocardial eccentric hypertrophy, rather than true dilatation, is evidenced by increased heart weight: body weight ratio, together with a decreased ratio of the left ventricular thickness to chamber diameter\(^{18}\).

An example of histology from the normal canine myocardium is shown in Figure 1A. Some studies on histopathological findings in the myocardium of dogs with the clinical diagnosis of DCM report non-specific findings\(^{19}\). This is consistent with the histopathological findings of human idiopathic DCM, where the degree of fibrosis, degeneration and fibre attenuation may be variable\(^{20,21}\). In dogs, however, two distinct histopathological forms of DCM have been described by various authors:

**The attenuated wavy fibre type of DCM** has been described by several authors in a total of 119 dogs of many giant-, large- and medium-sized breeds (including some boxers and Dobermanns)\(^{22-24}\). The myocardial lesions associated with the attenuated wavy fibre type of DCM consist of myocytes that are thinner than normal (≤ 6 µm in diameter) with a wavy appearance, comprising at least half of the thickness of the myocardial specimens from the upper
most commonly reported for non-syndromic DCM in humans (i.e. not associated with skeletal myopathy or other phenotype), with over thirteen different loci described. In a study of 37 dogs with DCM only three of 27 tested variables were shown to influence survival, i.e. young age at presentation, dyspnoea and absence of clinical signs evident to the owner or veterinary surgeon. These studies did not find breed (e.g. Dobermanns) or parameters of systolic function to be significant prognostic indicators in canine DCM. Survival times in different studies are compared in Table 1. Survival rate at one year was exceptionally low in a study of Dobermanns, which may indicate that the fatty infiltration - degenerative type of DCM carries a worse prognosis compared with the attenuated wavy fibre type of DCM (see histopathology section). Medical treatment, especially ACE inhibitors and beta-blockers, may influence survival in dogs with congestive heart failure, but this was only evaluated in two of the studies. However, as the administration of ACE inhibitors and beta-blockers varied considerably, this may also be a source of variation of survival times between the studies (Table 1). Histopathological characteristics of DCM

An example of histology from the normal canine myocardium is shown in Figure 1A. Some studies on histopathological findings in the myocardium of dogs with the clinical diagnosis of DCM report non-specific findings. This is consistent with the histopathological findings of human idiopathic DCM, where the degree of fibrosis, degeneration and fibre atrophy may be variable. In dogs, however, two distinct histopathological forms of DCM have been described by various authors: The attenuated wavy fibre type of DCM has been described by several authors in a total of 119 dogs of many giant-, large- and medium-sized breeds (including some boxers and Dobermanns). The myocardial lesions associated with the attenuated wavy fibre type of DCM consist of myocytes that are thinner than normal (< 6 µm in diameter) with a wavy appearance, comprising at least half of the thickness of the myocardial specimens from the upper and lower portions of the left ventricular wall. The myocytes are separated by a clear space, indicating oedematous fluid that is generally free from cellular infiltrates. The myocytes are separated by a clear space, indicating oedematous fluid, which is generally free from cellular infiltrates (Figure 1B). The presence of myocardial lesions associated with the attenuated wavy fibre type of DCM was found to have a very high sensitivity (98%) and specificity (100%) for DCM in a study of 70 dogs with clinical and echocardiographic diagnosis of DCM, when final diagnosis was made post mortem. As attenuated wavy fibres were not found in the myocardium of dogs with cardiac dilatation caused by heart disease other than DCM, this myocyte abnormality does not seem to be induced by chronic volume overload and stretching of the myocyte, as has been suggested. Attenuated wavy fibres have been reported as a major histological finding in human DCM, although infrequently. Atrophy or attenuation of myofibers without a wavy appearance has also been described. As attenuated

**Table 1 - Comparisons between studies of survival in dogs with DCM.**

<table>
<thead>
<tr>
<th>Number of dogs</th>
<th>Median survival time</th>
<th>Survival rate at one year</th>
<th>Percentage of dogs given ACE inhibitors</th>
<th>Percentage of dogs given beta-blockers</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 Dogs</td>
<td>50 days</td>
<td>35%</td>
<td>27%</td>
<td>11%</td>
</tr>
<tr>
<td>38 Breeds</td>
<td>65 days</td>
<td>55%</td>
<td>38%</td>
<td>15%</td>
</tr>
<tr>
<td>27 Breeds</td>
<td>90 days</td>
<td>75%</td>
<td>100%</td>
<td>50%</td>
</tr>
<tr>
<td>38 Breeds</td>
<td>120 days</td>
<td>90%</td>
<td>90%</td>
<td>90%</td>
</tr>
<tr>
<td>100 Dogs</td>
<td>150 days</td>
<td>90%</td>
<td>100%</td>
<td>100%</td>
</tr>
</tbody>
</table>

* ISACHC class , NYHA class, Dobe = Dobermanns

**Figure 1A** - Histology specimen from the myocardium of a dog which had no evidence of cardiac disease. Haematoxylin & Eosin stain. Size bar = 100 µm.

**Figure 1B** - Histology specimen from the myocardium of a dog with a fatty infiltration-degenerative type of canine idiopathic DCM. Vacuolisation and fragmentation of myocytes as well as prominent proliferation of connective tissue are evident. Trichrome stain. Size bar = 100 µm.

**Figure 1C** - Histology specimen from the myocardium of a dog with the fatty infiltration-degenerative type of canine idiopathic DCM. Myocardial infiltration of oedematous fluid, which is generally free from cellular infiltrates (Figure 1B).
wavy fibres have been found in the myocardium of dogs prior to any clinical or echocardiographic evidence of disease, it has been proposed that they represent an early DCM lesion.

The fatty infiltration - degenerative type of DCM was first described in 64 Boxers by Harpster in 1983. The presence of myocardial lesions associated with the fatty infiltration - degenerative type of DCM, i.e. the cardiomyopathy of boxers, include myocytolysis, myofibre degeneration, vacuolization and myocyte atrophy with extensive fibrosis and fatty infiltration. The lesions have been compared to isolated right ventricular cardiomyopathy in dogs and in humans. Four different reports on histological examinations of a total of 64 Doberman Pinschers with DCM describe findings similar to the cardiomyopathy of Boxers, i.e. fibrosis, fatty infiltration, myofibre degeneration, myocyte atrophy, and sometimes vacuolization. These features resemble those described for arrhythmogenic right ventricular cardiomyopathy in humans, which may affect the entire myocardium in later stages.

Differentiating between histologically different types of DCM may not be of major clinical importance, but is of great scientific importance as it may increase our knowledge concerning the aetiology and the pathogenesis of canine DCM.

Clinical findings in dogs with DCM

The two phases of canine DCM, dichotomised by the presence or absence of clinical signs, should be identified separately.

Pre-clinical DCM

This is the long asymptomatic phase prior to development of clinical signs. It has previously been referred to as occult DCM by some authors. However, the term “occult” implies that it cannot be identified by any clinical test, and so the authors prefer the term “preclinical”.

Overt DCM

This is the phase associated with the presence of clinical signs.

Clinical characteristics of dogs with overt DCM

Clinical signs in dogs with DCM and congestive heart failure (CHF) include breathlessness or dyspnoea, cough, depression, exercise intolerance, inappetence, syncope, weight loss, abdominal distention, and polydipsia. Clinical examination commonly reveals dyspnoea, tachypnoea, rales, crackles and increased breath sounds, tachycardia, arrhythmia, and, in some dogs, a systolic murmur of low to moderate intensity (grade I-III/VI). Further findings may include diastolic gallops or an audible third heart sound (S3), weak femoral arterial pulses, pulse deficit, ascites and distension of the jugular veins, pale mucous membranes, weight loss and muscle wasting and, sometimes, elevation of the body temperature. The clinical presentation may vary from case to case and according to breed.

Laboratory findings in dogs with overt DCM

Evaluation of haematology and blood chemistry is important in dogs with DCM to exclude other primary or concurrent disease. There may be no abnormalities; in the majority of dogs, routine biochemical analysis and haematology are within the reference ranges. Laboratory abnormalities may reflect the effects of low cardiac output, congestion, and neurohormonal activation. Increases in blood urea may be detected in some dogs, possibly a sign of prerenal azotaemia due to low cardiac output. Serum concentrations of biochemical markers of myocardial damage, such as Troponin I, may be within the normal reference range or slightly increased in dogs with DCM. Thus, significantly increased concentrations in a patient with suspected DCM should raise the suspicion of causes other than DCM, such as myocarditis or myocardial infarction, to explain echocardiographic findings of ventricular hypokinesia and dilatation. Alternatively, myocardial infarction may occur as a complication of DCM. Plasma concentrations of thyroid stimulating hormone (TSH) and total thyroxine (TT4) are within the normal limits in the majority of dogs with DCM. Increased circulating neurohormones have been detected in dogs with DCM, and in the future evaluation of these may become routine.

Electrocardiographic findings in dogs with overt DCM

In general, the electrocardiogram and the presence of ECG abnormalities have limited value in the diagnosis of DCM, but an ECG is essential for the evaluation of arrhythmias. Most dogs with DCM do show abnormalities on ECG recordings, such as the presence of arrhythmias, abnormal amplitude or duration of P wave or the QRS complex indicating chamber enlargement or conduction abnormalities. Atrial fibrillation is the most commonly diagnosed arrhythmia in dogs with DCM. The presence of ventricular premature complexes (VPCs) and ventricular tachycardia is reported in the majority of Boxers and Dobermanns. With the increased use of 24-hour ambulatory ECG (Holter) recordings, the true prevalence of arrhythmias in dogs with DCM may become better established.

Screening by Electrocardiography and Holter monitoring for dogs with Pre-Clinical DCM

In most breeds, the electrocardiogram is neither sensitive nor specific for the identification of dogs destined to develop DCM or those with asymptomatic disease. Electrocardiography has been shown to be useful in certain breeds, notably Boxers and Dobermanns. A single ECG trace is not useful, since it corresponds to a small fraction of the dog’s rhythm over a 24 hour period, and identification of abnormalities may be entirely fortuitous. Holter monitoring, a 24 hour ECG recording, is required.
wavy fibres have been found in the myocardium of dogs prior to any clinical or echocardiographic evidence of disease, it has been proposed that they represent an early DCM lesion.

The fatty infiltration - degenerative type of DCM was first described in 64 Boxers by Harpster41 in 1983. The presence of myocardial lesions associated with the fatty infiltration - degenerative type of DCM, i.e. the cardiomyopathy of boxers, includes myocytolysis, myofibre degeneration, vacuolization and myocyte atrophy with extensive fibrosis and fatty infiltration42,43. The lesions have been compared to those occurring in the body temperature50. The presence of intramyocyte wavy fibres have been found in the myocardium of dogs and in humans. Four different reports on histological examinations of a total of 64 Doberman Pinschers with DCM describe findings similar to the cardiomyopathy of Boxers, i.e. fibrosis, fatty infiltration, myocytolysis, myocyte atrophy, and sometimes vacuolization43,44,45,46 (Figure 1C).

These features resemble those described for arthromycotic right ventricular cardiomyopathy in humans, which may affect the entire myocardium in later stages41.

Differentiating between histologically different types of DCM may not be of major clinical importance, but is of great scientific importance as it may increase our knowledge concerning the aetiology and the pathogenesis of canine DCM.

Clinical findings in dogs with DCM

The two phases of canine DCM, dichotomised by the presence or absence of clinical signs, should be identified separately.

Pre-clinical DCM

This is the long asymptomatic phase prior to development of clinical signs. It has previously been referred to as occult DCM by some authors47. However, the term "occult" implies that it cannot be identified by any clinical test, and so the authors prefer the term "preclinical".

Overt DCM

This is the phase associated with the presence of clinical signs.

Clinical characteristics of dogs with overt DCM

Clinical signs in dogs with DCM and congestive heart failure (CHF) include breathlessness or dyspnea, cough, depression, exercise intolerance, inappetence, syncope, weight loss, abdominal distention, and polydipsia. Clinical examination commonly reveals dyspnea, tachypnea, rales, crackles and increased breath sounds, tachycardia, arhythmia, and, in some dogs, a systolic murmur of low to moderate intensity (grade I-III/VI). Further findings may include diastolic gallops or an audible third heart sound (S3), weak femoral arterial pulses, pulse deficit, ascites and distension of the jugular veins, pale mucous membranes, weight loss and muscle wasting and, sometimes, elevation of the body temperature48. The clinical presentation may vary from case to case and according to breed.

Laboratory findings in dogs with overt DCM

Evaluation of haematology and blood chemistry is important in dogs with DCM to exclude other primary or concurrent disease. There may be no abnormalities; in the majority of dogs, routine biochemical analysis and haematology may not be diagnostic. Laboratory abnormalities may reflect the effects of low cardiac output, congestion, and neurohumoral activation. Increases in blood urea may be detected in some dogs, possibly a sign of preterminal azotemia due to low cardiac output. Serum concentrations of biochemical markers of myocardial damage, such as Troponin I, may be within the normal reference range or slightly increased with DCM47. Thus, significantly increased concentrations in a patient with suspected DCM should raise the suspicion of causes other than DCM, such as myocarditis or myocardial infarction, to explain echocardiographic findings. Markers of myocardial hypokinesia and dilatation. Alternatively, myocardial infarction may occur as a complication of DCM. Plasma concentrations of thyroid stimulating hormone (TSH) and total thyroxine (TT4) are within the normal limits in the majority of dogs with DCM49. Increased circulating neurohormones have been detected in dogs with DCM, and in the future evaluation of these may become routine50.

Electrocardiographic findings in dogs with overt DCM

In general, the electrocardiogram and the presence of ECG abnormalities have limited value in the diagnosis of DCM, but an ECG is essential for the evaluation of arrhythmias. Most dogs with DCM do show abnormalities on ECG recordings, such as the presence of arrhythmias, abnormal amplitude or duration of P wave or the QRS complex indicating chamber enlargement or conduction abnormalities. Atrial fibrillation is the most commonly diagnosed arrhythmia in dogs with DCM. The presence of ventricular premature complexes (VPCs) and ventricular tachycardia is reported in the majority of Boxers and Dobermanns. With the increased use of 24-hour ambulatory ECG (Holter) recordings, the true prevalence of arrhythmias in dogs with DCM may become better established.

Screening by Electrocardiography and Holter monitoring for dogs with Pre-Clinical DCM

In most breeds, the electrocardiogram is neither sensitive nor specific for the identification of dogs destined to develop DCM or those with asymptomatic disease. Electrocardiography has been shown to be useful in certain breeds, notably Boxers42,43,44 and Dobermanns42,44. A single ECG trace is not useful, since it corresponds to a small fraction of the dog's rhythm over a 24 hour period, and identification of abnormalities may be entirely fortuitous. Holter monitoring, a 24 hour ECG recording, is required45.

Evidence of ventricular arrhythmia precedes echocardiographic evidence of DCM in the Dobermann by some months or even years50,51. In Dobermanns, therefore, Holter monitoring is of proven value in the identification of dogs destined to develop DCM and guidelines have been produced for this breed for acceptable number of VPCs over a 24 hour period50. Similar longitudinal studies of prove that ventricular arrhythmia as well as more classical DCM are lacking in the Boxer although this progression has been proposed42,44. Over 50 ventricular premature complexes over 24 hours is likely to be abnormal in any age of Boxer42. In the Boxer, the detection of ventricular ectopy precedes the development of clinical signs by 3 - 4 years42. There appear to be geographical differences in the presentation of "Boxer cardiomyopathy". In contrast to the presented American Boxers, in Europe no atrial fibrillation or ventricular arrhythmia has been identified in North American Boxers, with minimal chamber dilatation or hypokinesia evident on echocardiography49,50. European Boxers present with congestive heart failure and these more classical features of DCM51.

Other breeds which frequently show ventricular ectopy in which Holter monitoring may be useful, include Weimaraners and great Danes, but guidelines have not yet been drawn up. In all breeds, it should be recognised that the presence of ventricular ectopy may reflect other potential causes and presence of these must be excluded.

Other electrocardiographic techniques which are being assessed to identify dogs at risk for development of ventricular arrhythmias or dilated cardiomyopathy include assessment of heart rate variability60,61,62,63, the presence of late complexes over 24 hours is likely to be abnormal in any age of Boxer42. In the Boxer, the detection of ventricular ectopy precedes the development of clinical signs by 3 - 4 years42. There appear to be geographical differences in the presentation of "Boxer cardiomyopathy". In contrast to the presented American Boxers, in Europe no atrial fibrillation or ventricular arrhythmia has been identified in North American Boxers, with minimal chamber dilatation or hypokinesia evident on echocardiography49,50. European Boxers present with congestive heart failure and these more classical features of DCM51.

Radiographic findings in dogs with DCM

Findings on thoracic radiography in dogs with overt DCM include, with significant ventricular dilation, the prominence of the left atrium, venous congestion, various degrees of interstitial or alveolar pulmonary oedema, and sometimes pleural effusion and ascites. These findings are diagnostic for left-sided or biventricular congestive heart failure, but are not specific for DCM. Radiography in dogs with pre-clinical DCM is frequently unremarkable although left atrial and / or left ventricular enlargement may be identified.

Echocardiographic diagnosis of dogs with DCM

The diagnosis of DCM is based on the identification of myocardial (predominantly but not solely systolic) dysfunction with the active exclusion of other acquired or congenital cardiac disease. Diagnosis of DCM in a predisposed breed once the patient is symptomatic is not problematic, and echocardiography is the most sensitive method of confirming myocardial dysfunction. Diagnosing the presence of myocardial failure and specific chamber dilatation requires 2D and M-mode echocardiography. However, Doppler echocardiography is required to exclude other significant congenital or acquired cardiac disease which results in a similar phenotype. It should be appreciated that the echocardiographic diagnosis of chamber dilatation and myocardial failure is not specific for DCM; there are uncommon instances of ischaemic cardiomyopathy or myocarditis which are not routinely excluded by veterinary cardiologists other than at necropsy. A confirmed diagnosis of DCM should not be made without active exclusion of other causes of the dilated, hypokinetic heart (Table 2).

The authors recommend that full 2D, M-mode and Doppler echocardiography is carried out with the patient lying in lateral recumbency, scanning through the dependent chest wall, without chemical restraint. It is noted that some operators prefer to perform certain giant breed dogs standing, although lateral recumbency is strongly recommended to ensure thorough and repeatable examinations. M-mode measurements should be obtained according to the recommendations of the American Society of Echocardiography52. Two-dimensional echocardiography should be carried out according to ACVIM Cardiology Specialty guidelines53. Maximal left ventricular (LV) lengths and volumes are usually obtained from long-axis views compared with left apical views54 and the authors recommend that calculations for left ventricular volumes, ejection fraction and sphericity indices are obtained from whichever view optimises LV length and volume. Five

Table 2: Exclusion Criteria Prior to Making a Diagnosis of Idiopathic Dilated Cardiomyopathy

<table>
<thead>
<tr>
<th>Congenital and other acquired heart diseases</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Tachyarrhythmias which may result in a tachycardia induced cardiomyopathy</td>
<td></td>
</tr>
<tr>
<td>Systemic hypertension</td>
<td></td>
</tr>
<tr>
<td>Persistent and substantial left ventricular outflow tract obstruction that may be secondary to: heart failure</td>
<td></td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td></td>
</tr>
<tr>
<td>Diseases that might affect cardiovascular function (e.g. hypothyroidism)</td>
<td></td>
</tr>
<tr>
<td>History of use of drugs known to affect cardiac function (e.g. doxorubicin)</td>
<td></td>
</tr>
<tr>
<td>Identifiable cardiac cause (e.g. congenital heart disease)</td>
<td></td>
</tr>
<tr>
<td>Presence of atrial fibrillation with a fractional shortening &lt; 25% (mean of 5 to 10 beats)</td>
<td></td>
</tr>
</tbody>
</table>

Note, these criteria can be simply and practically excluded in the living dog. At post mortem, other criteria should actively excluded, but should be considered in the evaluation of heart failure.
cardiac cycles should be evaluated to generate mean measurements for each parameter. In atrial fibrillation, 10 cardiac cycles should be measured.

**Reference ranges of cardiac chamber dimensions**

Echocardiography is used to define normal cardiac dimensions based on normal reference values. These data can be used to define both pre-clinical and overt DCM cases. Currently, many of the available reference values are based on a mixture of breeds and body sizes, although the extreme body sizes are often under-represented. Breed specific data are sparse in the literature and breed specific reference ranges are urgently required to obtain the more narrow reference ranges required for M-mode dimensions or two-dimensional echocardiographic derived left ventricular volumes or ejection fraction. Furthermore, prospective studies are required to assess the sensitivity and specificity of deviations from these reference values as predictive criteria for the development of DCM. Linear regression equations and graphs with confidence intervals are required for consultation for specific breeds. The influence of other variables such as age, body condition, gender and heart rate need to be evaluated in specific breeds.

Breed specific echocardiographic data are available for the following breeds: Afghan Hounds, Beagles, Boxers, Cavalier King Charles Spaniels, Cocker Spaniels (English), Corgi (Pembroke), Deerhounds, Dobermanns, Golden Retrievers, great Danes, Greyhounds, Irish Wolfhounds, Newfoundlands and Poodles (miniature). However, it should be realised that serial monitoring to confirm normality was only carried out in a small number of these studies, over a limited time period.

In general, in man, the cut-off for diagnosing left ventricular enlargement is >112% predicted values based on height and age, corresponding to over two standard deviations above reference values. In a specific breed, using a cut-off value exceeding two standard deviations above the mean reference value is rather conservative but may be useful until more specific linear regression equations are generated. In a range of dog breeds, allometric scaling of M-mode variables has been assessed, with LV M-mode dimensions showing a linear relationship with body weight. This formula needs to be prospectively evaluated in breeds at risk of developing DCM to assess its predictive value.

**Evaluation of left ventricular systolic function**

In the veterinary literature, most studies in dogs use fractional shortening as the major indicator of systolic function. In dogs, values of less than 20 to 25% are considered to be abnormally low and to represent systolic dysfunction. However, in the presence of significant mitral regurgitation, fractional shortening may be misleading.

In humans, ejection fraction is quoted as the main parameter assessing systolic function and ejection fractions (calculated on echo from apical views using Simpson's rule in most studies) are said to be abnormal at values ranging from less than 40% to less than 50%. In dogs, the authors consider that an ejection fraction less than 40% is abnormally low.

Note that this is determined from 2D echocardiographic images obtained from a right parasternal long axis four chamber view (Figure 2).

The end-diastolic and end-systolic ventricular volumes can be normalised to body surface area (BSA) to give an end-diastolic volume index and an end-systolic volume index (EDV-I and ESV-I) in units mls / m². The formula to calculate canine BSA from body weight (Wt) in grammes is:

\[ BSA (m^2) = 10.1 \times \left( \frac{Wt(grammes)}{10^4} \right)^{0.667} \]


An ESV-I over 80 ml/m² offers unequivocal evidence for systolic dysfunction, although this may be an excessively conservative value, as the normal canine ESV-I has been suggested to be <30 ml/m².

**Evaluation of Diastolic Function**

To the authors’ knowledge, abnormalities in diastolic function do not appear to precede the systolic dysfunction or changes in chamber dimensions in dogs developing DCM. Pulsed wave Doppler of mitral inflow and pulmonary venous flow to assess diastolic function is not, therefore, required as a screening test to identify animals with pre-clinical DCM. In dogs with overt DCM, however, the authors believe that evaluation of diastolic function will be increasingly recognised as being important in determining prognosis. It has been recently shown that human patients with DCM have not only poor systolic function, but also...
Echocardiography is used to define abnormal cardiac dimensions based on normal reference values. These data can be used to define both pre-clinical and overt DCM cases. Currently, many of the available reference values are based on a mixture of breeds and body sizes, although the extreme body sizes are often under-represented. Breed-specific data are sparse in the literature and breed-specific reference ranges are urgently required to obtain the more narrow reference ranges required for M-mode dimensions or two-dimensional echocardiographic derived left ventricular volumes or ejection fraction. Furthermore, prospective studies are required to assess the specificity and sensitivity of deviations from these reference values as predictive criteria for the development of DCM. Linear regression equations and graphs with confidence intervals are required for consultation for specific breeds. The influence of other variables such as age, body condition, gender and heart rate need to be evaluated in specific breeds.

Breed-specific echocardiographic data are available for the following breeds: Afghan Hounds, Beagles, Bassets, Cavalier King Charles Spaniels, Cocker Spaniels (English), Corgi (Pembroke), Deerhounds, Dobermanstms, Golden Retrievers, great Danes, Greyhounds, Irish Wolfhounds, Newfoundlandstms and Poodles (miniature). However, it should be realised that serial monitoring to confirm normality was only carried out in a small number of these studies, over a limited time period.

In general, in man, the cut-off for diagnosing left ventricular enlargement is >112% predicted values based on height and age, corresponding to over two standard deviations above reference values. In a specific breed, using a cut-off value exceeding two standard deviations above the mean reference value is rather conservative but may be useful until more specific linear regression equations are generated. In a range of dog breeds, allometric scaling of M-mode variables has been assessed, with LV M-mode dimensions showing a linear relationship with body weight1/3 (83). This formula needs to be applied to the authors suggest a scoring system which may be of use in breed schemes screening for DCM. Therefore, the following features are commonly identified in confirmed overt DCM.

1. Left ventricular enlargement (increased LVIDd).
2. Depressed systolic function.
3. Altered geometry of the left ventricle (increased sphericity).

A subjective assessment is often made, but a quantitative method is preferred. The authors propose that a ratio of LV diastolic length (from right parasternal (RPS) long axis four chamber view) to the M-mode LV diastolic dimension (LVIDd) >1.65 represents increased sphericity. Preliminary data from dogs indicated that a restrictive trans-mitral flow pattern despite treatment of heart failure is also associated with a poor prognosis in humans.

The end-diastolic and end-systolic ventricular volumes can be normalised to body surface area (BSA) to give an end-diastolic volume index and an end-systolic volume index (EDVI and ESVI) in units ml/m2. The formula to calculate canine BSA from body weight (Wg) in grammes is:

\[\text{BSA (m}^2\text{)} = 10.1 \times (\text{Wg(grammes)})^{0.667} \times 10^{-4}\]

Note that this is determined from 2D echocardiographic images obtained from a right parasternal long axis four chamber view (Figure 2).

The end-diastolic and end-systolic ventricular volumes can be normalised to body surface area (BSA) to give an end-diastolic volume index and an end-systolic volume index (EDVI and ESVI) in units ml/m2. The formula to calculate canine BSA from body weight (Wg) in grammes is:

\[\text{BSA (m}^2\text{)} = 10.1 \times (\text{Wg(grammes)})^{0.667} \times 10^{-4}\]


An ESVI over 80 ml/m2 offers unequivocal evidence for systolic dysfunction, although this may be an excessively conservative value, as the normal canine ESVI has been suggested to be <30 ml/m2.

**Evaluation of Diastolic Function**

To the authors’ knowledge, abnormalities in diastolic function do not appear to precede the systolic dysfunction or changes in chamber dimensions in dogs developing DCM. Pulsed wave Doppler of mitral inflow and pulmonary venous flow to assess diastolic function is not, therefore, required as a screening test to identify animals with preclinical DCM. In dogs with overt DCM, however, the authors believe that evaluation of diastolic function will be increasingly recognised as being important in determining prognosis. It has been recently shown that human patients with DCM have not only poor systolic function, but also abnormal diastolic function. Moreover, it has become increasingly clear that abnormalities of diastolic function play a major role in producing signs and symptoms in human patients presenting with congestive heart failure. Doppler study of trans-mitral flow and pulmonary venous flow has emerged as an increasingly used method for the non-invasive evaluation of diastolic filling patterns in humans. The restrictive filling pattern is the most common pattern in patients with DCM and correlates well with high filling pressure and poor prognosis in people. In particular E wave deceleration time appears a powerful independent predictor of poor prognosis in patients with left ventricular dysfunction, whether symptomatic or asymptomatic, even in patients with atrial fibrillation. Finally, the persistence of the restrictive trans-mitral flow filling pattern despite treatment of heart failure is also associated with a poor prognosis in humans.

Preliminary data from dogs indicated that a restrictive pattern on mitral inflow and a short E wave deceleration time (<80 milliseconds) were significantly associated with a poor prognosis (both parameters, p<0.001). This study did not find that any of the standard echocardiographic parameters (fractional shortening, mitral E/FSS, ESV-I and EDVI) influenced survival.

**Making the Diagnosis of DCM**

Other congenital, acquired and systemic conditions must initially be excluded, as listed in Table 2. Because of the high prevalence of DCM and echocardiographic abnormalities, the stringent diagnosis of DCM generally requires all of the following:

1. Left ventricular dilation (especially in systole but also in diastole).
2. Depressed systolic function.
3. Increased mitral valve M-mode E point to septal separation (EPSS).
4. Left or bi-atrial enlargement.
5. Increased mitral valve M-mode E point to septal separation (EPSS).
6. Arrhythmias recorded on the simultaneous ECG through the echocardiographic examination or during routine ECG or Holter recording are supportive of the presence of DCM. Arrhythmias are more important as a criterion for the diagnosis of DCM in certain breeds, especially ventricular arrhythmias in Dobermanns and Boxers and atrial fibrillation in Irish Wolfhounds.

In dogs presenting with congestive heart failure or other manifestations of DCM, it is normally possible to meet these criteria and to make an unequivocal diagnosis (although subsequent post-mortem confirmation is recommended). However, veterinary cardiologists are increasingly being presented with dogs with more equivocal findings, perhaps from breed schemes screening for DCM. Therefore, the authors propose a scoring system which may be of use in...
determining whether a particular patient is likely to have pre-clinical DCM or echocardiographic abnormalities which may precede pre-clinical DCM. Such a scoring system may be of use in serial evaluation or longitudinal screening of a population of dogs in ascertaining the presence of progressive disease, as expected in DCM.

A scoring system for the diagnosis of DCM?

It is apparent that in both dogs and humans, echocardiographic abnormalities or the classical echocardiographic findings of DCM may be identified for a considerable time before the patient becomes clinically affected. The identification of such abnormalities poses a problem. Where echocardiography is used as a method of phenotyping in genetic studies of canine DCM, accuracy is essential. One has to be certain that dogs showing these abnormalities have the disease. Advice to breeders on the status of their dog is similarly fraught with difficulties. One solution is to establish a scoring system.

In humans, an arbitrary number of major and minor criteria for the diagnosis of DCM were proposed over a decade ago by Lestuzzi and colleagues[91]. The major criteria were based on the LV systolic or diastolic dimensions exceeding 95% confidence intervals of the normal M-mode values (for height and age) and a fractional shortening of less than 26%. Minor criteria included M-mode dimensions exceeding 80% confidence intervals, moderately reduced fractional shortening, enlarged left atrium, and a rounded LV chamber. Using slightly modified criteria, a European collaboration have proposed that the diagnosis of familial dilated cardiomyopathy is fulfilled by either (i) one major criterion or (ii) LV dilatation and one minor criterion or (iii) three minor criteria[92]. Additional minor criteria include the presence of arrhythmias or conduction disturbances and segmental wall motion abnormalities. The active exclusion of other causes of myocardial dysfunction or chamber enlargement is emphasised for a reliable diagnosis. These criteria have been assessed prospectively in investigation of familial DCM in French families[93].

We propose that modified criteria will be similarly useful in screening for the canine disease, but these will need to be assessed prospectively. They may require to be modified for specific breeds.

Prior to using these criteria, it is essential that there is active exclusion of other congenital or acquired cardiac diseases and other systemic conditions, which may have secondary effect on the heart. See Table 2.

Proposed major criteria for the diagnosis of canine DCM

1. Left ventricular M-mode systolic or diastolic dimensions exceeding 95% confidence intervals for the individual based on regression equations or predicted reference values, or outside other established breed-specific reference ranges. Account should also be paid to the influence within specific breeds of body surface area, gender or age where these data are available and applicable.

2. Increased sphericity: LV length: M-mode LV diastolic dimensions is decreased.

The authors propose that a ratio of LV diastolic length (from RPS long axis four chamber view) to the M-mode LV diastolic dimension <1.65 represents increased sphericity[94].

3.a. EITHER:

M-mode fractional shortening of <20% or 25% (depending on breed-specific reference values).

3.b. AND / OR:

Left ventricular ejection fraction less than 40%.

It is important that breed specific reference ranges are generated or consulted if available. The authors urge particular caution in assessing extreme breeds, or very athletic breeds (which, at rest, often have a low measured fractional shortening).

Proposed minor criteria for the diagnosis of canine DCM

1. The presence of an arrhythmia in a specific breed where the arrhythmia has been shown to be strongly associated with DCM (e.g. increased (for age) ventricular ectopy in Dobermanns or Boxers). Other (cardiac or systemic) causes for ventricular ectopy should be actively excluded.

2. Atrial fibrillation.

3. Increased mitral valve M-mode E point to septal separation (EPSS).

4. PEP:ET ratio increased over 95% confidence intervals (e.g. over 0.4)

5. M-mode fractional shortening in equivocal range (depending on breed-specific references).

6. Left or bi-atrial enlargement

It must be emphasised that other cardiac or systemic disease, including systemic hypertension, must be excluded as far as possible before a firm diagnosis of DCM may be made. The presence of persistent tachyarrhythmias, such as atrial fibrillation, which may result in myocardial failure, must also be considered. They may be the cause or the consequence of myocardial dysfunction and careful consideration of their presence is required prior to making a diagnosis of DCM.

If major criteria score 3 points and minor criteria score 1 point each, a total score of SIX or more should identify dogs with DCM but this must be assessed for various breeds prospectively. Further refinements with number loading of some criteria are possible in certain breeds.

The authors emphasise that the identification of one or more of these major or minor criteria should prompt the cardiologist to serially examine that animal for evidence of progression, which should be identified over some years if DCM is genuinely present. The score should increase over time. Prospective evaluation of screened dogs is recommended by a number of centres to evaluate the usefulness of our proposed criteria in screening for DCM. At this stage, these criteria should be assessed for the diagnosis of DCM, and should not be interpreted as being breeding guidelines.
determining whether a particular patient is likely to have pre-clinical DCM or echocardiographic abnormalities which may precede pre-clinical DCM. Such a scoring system may be of use in serial evaluations, suggesting screening of a population of dogs in ascertaining the presence of progressive disease, as expected in DCM.

A scoring system for the diagnosis of DCM? It is apparent that in both dogs and humans, echocardiographic abnormalities or the classical echocardiographic findings of DCM may be identified for a considerable time before the patient becomes clinically affected. The identification of such animals poses a problem. Where echocardiography is used as a method of phenotyping in genetic studies of canine DCM, accuracy is essential. One must be certain that dogs showing these abnormalities have the disease. Advice to breeders on the status of their dog is similarly fraught with difficulties. One solution is to establish a scoring system.

In humans, an arbitrary number of major and minor criteria for the diagnosis of DCM were proposed over a decade ago by Lestuzzi and colleagues2. The major criteria were based on the LV systolic or diastolic dimensions exceeding 95% confidence intervals of the normal M-mode values (for height and age) and a fractional shortening of less than 26%. Minor criteria included M-mode dimensions exceeding 80% confidence intervals, moderately reduced fractional height and age) and a fractional shortening of less than 26%. Major criteria were proposed that the diagnosis of familial dilated cardiomyopathy is fulfilled by either (i) one major criterion or (ii) LV dilatation and one minor criterion or (iii) three cardiomyopathy is fulfilled by either (i) one major criterion

The genetic basis of DCM: the reason for screening

Canine DCM has long been suspected to be an inherited disease and therefore to have a genetic basis, because of its prevalence in pedigree dog breeds, and in specific families within these breeds. In most breeds, an autosomal dominant mode of transmission is reported, despite the inbred nature of most canine pedigrees predisposing them to recessive conditions. This includes DCM in Irish wolfhounds, Dobermanns and Newfoundlandsp and ventricular arrhythmias of Border collies. A well-documented autosomal recessive transmission, with identification of a single founder, has been reported for Portuguese water dogs with a juvenile DCMp. An X-linked transmission has been proposed for dog breeds with DCM, where it should be noted that this study may include ascertainment bias, since siblings and litters were not prospectively screened. In Dobermanns, while the disease is recognised to be strongly familial, the actual mode of inheritance has proved difficult to elucidate for many of these families and may be recessive in othersq.

In man, over 30% cases of DCM are now appreciated to have a genetic basis (for reviews, see Refs 4 and 97). Some syndromic forms (with skeletal myopathy) are associated with X-linked inheritance, with known mutations in three genes. However, most non-syndromic familial forms of DCM have been associated with an autosomal dominant transmission. Over eleven different chromosome loci have been associated with the disease in some families by genetic linkage analysis, although the corresponding gene defect has only been identified for a few of these. A number of genes have been implicated in some small families, using non-positional candidate gene screening strategies. The proteins encoded by these genes comprise components of the cytoskeleton or the sarcolemma attachment to the cytoskeleton. It appears that DCM is likely to be due to cytoskeletal abnormalitiesr, which is consistent with the final phenotype (and the histological findings of attenuated wavy fibres). Screening candidate genes implicated in dilated cardiomyopathy is underway in a number of dog breeds (e.g. excluded genes include the cardiac actin and desmin genes in Dobermannsrs, candidate genes for arrhythmogenic right ventricular cardiomyopathy in boxers and the des-cytoplasmic gene in Dobermannsrs). A genome-wide linkage analysis is in progress in an informative Newfoundland family.

Proposed minor criteria for the diagnosis of canine DCM

1. The presence of an arrhythmia in a specific breed where the arrhythmia has been shown to be strongly associated with DCM (e.g. increased (for age) ventricular ectopy in Dobermanns or Boxers). Other (cardiac or systemic) causes for ventricular ectopy should be actively excluded.

2. Arrhythmia.

3. Increased mitral valve M-mode E point to septal separation (EPSS).

4. PEP/ET ratio increased over 95% confidence intervals (e.g. over 0.4).

5. M-mode fractional shortening in equivocal range (depending on breed-specific reference).

6. Left or bi-atrial enlargement.

It must be emphasised that other cardiac or systemic disease, including hypertension, must be excluded as far as possible before a firm diagnosis of DCM may be made. The presence of persistent tachyarrhythmias, such as atrial fibrillation, which may result in myocardial failure, must also be considered. They may be the cause or the consequence of myocardial dysfunction and careful consideration of their presence is required prior to making a diagnosis of DCM. If major criteria score 3 points and minor criteria score 1 point each, a total score of 5 or more should identify dogs with DCM but this must be assessed in various breeds prospectively. Further refinements with number loading of some criteria are possible in certain breeds.

The authors emphasise that the identification of one or more of these major or minor criteria should prompt the cardiologist to serially examine that animal for evidence of myocardial dysfunction, which should be identified over some years if DCM is genuinely present. The score should increase over time. Prospective evaluation of screened dogs is recommended by a number of centres to evaluate the usefulness of our proposed screening system. In this stage, these criteria should be assessed for the diagnosis of DCM, and should not be interpreted as being breeding guidelines.

Discussion

The authors have sought to develop some guidelines and diagnostic criteria for the diagnosis of DCM for use in screening programmes requested or initiated by some breed societies. These have been tested over a limited time in the authors’ own practices, but have not yet been critically reviewed by colleagues so the guidelines may be refined or adapted for different, specific breeds. It must be emphasised that DCM is a diagnosis of exclusion and other causes for the presence of dilated, hypokinetic heart should be actively ruled out, and post mortem confirmation of the diagnosis obtained whenever possible. Atrial fibrillation: an indicator of incipient myocardial disease or causal in the development of systolic dysfunction?

Further controversies are also introduced in this asymptomatic period. For example, dogs may be identified with atrial fibrillation without any significant echocardiographic changes. Atrial fibrillation may be an early indicator of the presence of myocardial disease, and the typical echocardiographic appearance of DCM later develops. This has been suggested in Irish Wolfhounds. It is possible that underlying myocardial disease is responsible for the atrial fibrillation, such as focal atrial cardiomyopathy or myocardial reciption. Atrial fibrillation may be related to some breeds.

Asynchronous atrial contraction is considered to be a normal finding in a variety of canine breeds, including German shepherds, dachshunds, cocker spaniels and a number of large breeds. However, this finding may also result in atrial fibrillation in some dogs. In these cases, atrial fibrillation may be associated with a strong familial component. The authors have sought to develop some guidelines and diagnostic criteria for the diagnosis of DCM for use in screening programmes requested or initiated by some breed societies. These have been tested over a limited time in the authors’ own practices, but have not yet been critically reviewed by colleagues so the guidelines may be refined or adapted for different, specific breeds. It must be emphasised that DCM is a diagnosis of exclusion and other causes for the presence of dilated, hypokinetic heart should be actively ruled out, and post mortem confirmation of the diagnosis obtained whenever possible.
Histological classification of DCM

The histological classification into two major types of DCM is attractive, since it is consistent with two major aetio-pathogenetic factors\textsuperscript{11,12}. However, this histopathological classification has still to be widely accepted by veterinary cardiac pathologists.

Presumably, different specific histological myocardial changes may reflect different disease processes in the myocardium, which may become elucidated by further studies on canine DCM. As the very structure of the myocytes is distorted in the attenuated wavy fibre type of DCM, the cause may be a defect in the cytoskeletal proteins. Mutations in genes encoding for cytoskeletal proteins have been implicated in dilated cardiomyopathy in humans and experimental models\textsuperscript{12}. The lack of abnormalities found in the actin gene in Doberman Pinschers\textsuperscript{13}, presumably affected with the fatty infiltration - degenerative type of DCM, does not preclude its involvement in the pathogenesis of the attenuated wavy fibre type of DCM, as such involvement has been shown in a small number of human patients with DCM\textsuperscript{14}.

It is important that dogs suspected from clinical and echocardiography/ Doppler examinations to have dilated cardiomyopathy should undergo post-mortem examination for a definitive diagnosis, particularly for dogs from families in genetic studies. Other conditions, such as myocardial infarct, severe arterio- or athero-sclerosis, post-myocarditis lesions may mimic dilated cardiomyopathy. Furthermore, mitral valve endocardiosis in large breed dogs is commonly associated with myocardial failure in the late stages. Categorization of dogs into one of the two histopathological classes of DCM, if applicable, will facilitate prospective studies into aetio-pathogenesis of this condition.

Echocardiographic abnormalities may precede unequivocal DCM

In both human and dog families, from various breeds, with prospective screening for the presence of familial DCM, it is common to identify minor echocardiographic abnormalities in relatives. Baig and colleagues\textsuperscript{15} divided these into “left ventricular enlargement” and “depressed fractional shortening” categories. Human relatives with left ventricular enlargement (with initially apparently normal systolic function) do progress to develop DCM and furthermore, show other abnormalities including histopathological changes\textsuperscript{12} and cardiovascular exercise variables\textsuperscript{13,16}. Much less investigation of the “depressed fractional shortening” relatives has been published, and they were initially dismissed as a limited manifestation of DCM\textsuperscript{15}. In dogs, similar abnormalities are noted in various breeds. In Newfoundlands, the depressed fractional shortening category is most common, with slow progression (over several years) documented in some individuals to eventually develop other criteria for the diagnosis of DCM. The left ventricular enlargement Newfoundlands progress more rapidly (usually within two years). Although fractional shortening and ejection fraction is normal in this latter group, the PEP:ET ratio is increased compared with normal dogs, showing that this may be a more specific predictor of systolic dysfunction\textsuperscript{17}. In view of this progression, the identification of echo abnormalities may be assigned a score, which, with other clinical or electrocardiographic abnormalities, may be used in prospectively screening dogs from families suffering from DCM, to identify individuals which require serial monitoring.

In our proposed scoring system designed to identify animals which should be serially monitored in longitudinal studies, to assess their prognostic significance in the identification of animals destined to develop DCM, we have deliberately identified rigorous criteria to avoid healthy dogs from being falsely identified as having DCM. Although these conservative criteria may fail to identify early asymptomatic DCM cases as being genuinely affected, the presence of a score should prompt serial evaluation of such animals, which should eventually progress to score six or more points to enable an unequivocal diagnosis of DCM.

Genetics

It is clear that studying the genetics of canine DCM should advance the understanding of human DCM. In man, there are many possible phenocopies (ischaemic cardiomyopathy, myocarditis, alcoholism etc.) which confound genetic analyses, whereas these are much more rare in canine families. Just as there have been a large number of loci and genes implicated in human DCM, it is probable that specific breeds will have different mutations in different genes although the recent evolution of dog breeds supports the likelihood that a single mutation is likely to be responsible for the disease within a given breed. In studying the genetic basis of DCM, a robust diagnosis is essential, and it is hoped that the guidelines provided here will facilitate such studies.

Conclusions

The breed differences in DCM, both in manifestations and clinical course, make it unlikely that identical criteria apply to all breeds. However, our scoring system and these criteria offer veterinary cardiologists a starting point for future studies. The criteria and the scoring system may be refined for specific breeds. It is probable that certain criteria will be weighted differently in certain breeds (e.g. ventricular arrhythmias in Dobermanns and Boxers may represent a major criterion). Furthermore, these criteria will provide a minimum data base aimed at increasing our knowledge about the natural history of the development of DCM in specific breeds, and identifying dogs which should be serially monitored. Longitudinal studies are required in specific breeds to prospectively determine the value of these proposals.

References

Histological classification of DCM

The histological classification into two major types of DCM is attractive, since it is consistent with two major aetiological factors. However, this histopathological classification has been widely accepted by veterinary cardiologists.

Presumably, different specific histological myocardial changes may reflect different disease processes in the myocardium, which may become elucidated by further studies on canine DCM. As the structure of the myocytes is distorted in the attenuated wavy fibre type of DCM, the cause may be a defect in the cytoskeletal proteins. Mutations in genes encoding for cytoskeletal proteins have been implicated in dilated cardiomyopathy in humans and experimental models. It is probable that some of these genes are also involved in the pathogenesis of the attenuated wavy fibre type of DCM, as such involvement has been shown in a small number of human patients with DCM.

It is important that dogs suspected from clinical and echocardiography/Doppler examinations to have dilated cardiomyopathy undergo post-mortem examination for a definitive diagnosis, particularly for dogs from families in genetic studies. Other conditions, such as myocardial infarct, severe arterio- or arterio- sclerosis, post-myocarditis lesions may mimic dilated cardiomyopathy. Furthermore, intravascular embolism in other organs is commonly associated with myocardial failure in the late stages. Categorization of dogs into one of the two histopathological classes of DCM, if applicable, will facilitate prospective studies into aetiopathogenesis of this condition.

Echocardiographic abnormalities may precede sequelae of DCM

In both human and dog families, from various breeds, with prospective screening for the presence of familial DCM, it is common to identify minor echocardiographic abnormalities in relatives. Buig and colleagues divided these into two “classical” and “depressed fractional shortening” categories. Human relatives with left ventricular enlargement (with initially apparently normal systolic function) develop DCM and furthermore, show other abnormalities including histopathological changes and cardiovascular exercise variables. Much less investigation of the “depressed fractional shortening” relates has been published, and they were initially dismissed as a limited manifestation of DCM. In dogs, similar abnormalities are noted in various breeds. In Newfoundlands, the depressed fractional shortening category, with slow progression (over several decades) were seen in some individuals to eventually develop other criteria for the diagnosis of DCM. The left ventricular enlargement Newfoundlands progress more rapidly (usually within a year). Although fractional shortening and ejection fraction is normal in this latter group, the PEP/ET ratio is increased compared with normal dogs, showing that this may be a more specific predictor of systolic dysfunction. In view of this progression, the identification of abnormal electro-physiological abnormalities may be a useful tool, which, with other clinical or electrocardiographic abnormalities, may be used in prospective screening dogs from families suffering from DCM, to identify individuals which require serial monitoring.

In our proposed scoring system designed to identify animals which should be serially monitored in longitudinal studies, to assess their prognostic significance in the identification of animals destined to develop DCM, we have deliberately identified rigorous criteria to avoid healthy dogs from being falsely identified as having DCM. Although these conservative criteria may fail to identify early asymptomatic DCM cases as being genuinely affected, the presence of a score should aid sequential evaluation of such animals, which should eventually progress to score six or more points to enable an unequivocal diagnosis of DCM.

Genetics

It is clear that studying the genetics of canine DCM should advance the understanding of human DCM. In man, there are many possible phenocopies (ischemic cardiomyopathy, mycarditis, alcoholism etc.) which confound genetic analyses, whereas these are much more rare in canine patients. It is probable that specific breeds will have different mutations in different genes although the recent evolution of dog breeds supports the likelihood that a single mutation is likely to be responsible for the disease within a given breed. In studying the genetic basis of DCM, a robust approach is essential, and it is hoped that the guidelines provided here will facilitate such studies.

Conclusions

The breed differences in DCM, both in manifestations and clinical course, make it unlikely that identical criteria apply to all breeds. However, our scoring system and these criteria offer veterinary cardiologists a major tool in the development of DCM. Furthermore, show other abnormalities including histopathological changes and cardiovascular exercise variables. Much less investigation of the “depressed fractional shortening” relates has been published, and they were initially dismissed as a limited manifestation of DCM. In dogs, similar abnormalities are noted in various breeds. In Newfoundlands, the depressed fractional shortening category, with slow progression (over several decades) were seen in some individuals to eventually develop other criteria for the diagnosis of DCM. The left ventricular enlargement Newfoundlands progress more rapidly (usually within a year). Although fractional shortening and ejection fraction is normal in this latter group, the PEP/ET ratio is increased compared with normal dogs, showing that this may be a more specific predictor of systolic dysfunction. In view of this progression, the identification of abnormal electro-physiological abnormalities may be a useful tool, which, with other clinical or electrocardiographic abnormalities, may be used in prospective screening dogs from families suffering from DCM, to identify individuals which require serial monitoring.

In our proposed scoring system designed to identify animals which should be serially monitored in longitudinal studies, to assess their prognostic significance in the identification of animals destined to develop DCM, we have deliberately identified rigorous criteria to avoid healthy dogs from being falsely identified as having DCM. Although these conservative criteria may fail to identify early asymptomatic DCM cases as being genuinely affected, the presence of a score should aid sequential evaluation of such animals, which should eventually progress to score six or more points to enable an unequivocal diagnosis of DCM.

Genetics

It is clear that studying the genetics of canine DCM should advance the understanding of human DCM. In man, there are many possible phenocopies (ischemic cardiomyopathy, mycarditis, alcoholism etc.) which confound genetic analyses, whereas these are much more rare in canine patients. It is probable that specific breeds will have different mutations in different genes although the recent evolution of dog breeds supports the likelihood that a single mutation is likely to be responsible for the disease within a given breed. In studying the genetic basis of DCM, a robust approach is essential, and it is hoped that the guidelines provided here will facilitate such studies.

Conclusions

The breed differences in DCM, both in manifestations and clinical course, make it unlikely that identical criteria apply to all breeds. However, our scoring system and these criteria offer veterinary cardiologists a major tool in the development of DCM. Furthermore, show other abnormalities including histopathological changes and cardiovascular exercise variables. Much less investigation of the “depressed fractional shortening” relates has been published, and they were initially dismissed as a limited manifestation of DCM. In dogs, similar abnormalities are noted in various breeds. In Newfoundlands, the depressed fractional shortening category, with slow progression (over several decades) were seen in some individuals to eventually develop other criteria for the diagnosis of DCM. The left ventricular enlargement Newfoundlands progress more rapidly (usually within a year). Although fractional shortening and ejection fraction is normal in this latter group, the PEP/ET ratio is increased compared with normal dogs, showing that this may be a more specific predictor of systolic dysfunction. In view of this progression, the identification of abnormal electro-physiological abnormalities may be a useful tool, which, with other clinical or electrocardiographic abnormalities, may be used in prospective screening dogs from families suffering from DCM, to identify individuals which require serial monitoring.

In our proposed scoring system designed to identify animals which should be serially monitored in longitudinal studies, to assess their prognostic significance in the identification of animals destined to develop DCM, we have deliberately identified rigorous criteria to avoid healthy dogs from being falsely identified as having DCM. Although these conservative criteria may fail to identify early asymptomatic DCM cases as being genuinely affected, the presence of a score should aid sequential evaluation of such animals, which should eventually progress to score six or more points to enable an unequivocal diagnosis of DCM.